Aventa Genomics, a joint venture of Arima Genomics and Protean BioDiagnostics, has launched Aventa FusionPlus, a next-generation sequencing (NGS) test for the detection of gene fusions, translocations, and rearrangements across 361 genes from the formalin-fixed, paraffin-embedded tissue of solid tumors.
Aventa FusionPlus is the first clinical application of the 3D genomics technology advanced by Arima Genomics. The 3D genomics technology incorporated into the assay preserves the spatial proximity of fused and rearranged genes, providing a hundredfold to thousandfold signal amplification and identification of novel breakpoints and fusion partners, according to Aventa. The test improves upon conventional testing methods such as fluorescent in situ hybridization (FISH) and RNA sequencing, revealing biomarkers that may be missed by these methods, Aventa added.
"In previously characterized tumor specimens from patients with no known actionable driver, the Aventa FusionPlus test detected potentially actionable variants in half of the cases," Aventa Genomics’ Executive Director Chris Roberts said in a statement. "The increase in diagnostic yield from detecting actionable biomarkers FISH and RNA sequencing ..., we believe, will provide more treatment options and will facilitate improved patient management."
The testing service will be performed in Aventa's CLIA-certified laboratory in Orlando, FL.
